Viatris

Yahoo Finance • 12 days ago

VBR Offers Greater Size While ISCV Pays Higher Yield

Key Points VBR is much larger and more liquid than ISCV, but comes with a slightly higher expense ratio. ISCV holds more stocks, while VBR has delivered stronger five-year growth. Both ETFs tilt toward small-cap value stocks, but sector w... Full story

Yahoo Finance • 25 days ago

Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials

Viatris (VTRS) said Thursday the US Food and Drug Administration approved octreotide acetate for inj PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 25 days ago

FDA Approves Viatris' Generic Sandostatin LAR Depot; To Review Weekly Contraceptive Patch Next July

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Thursday announced updates on its four regulatory milestones spanning across all stages of its global pipeline. -- The FDA has approved the company's octreotide acetate for injectable... Full story

Yahoo Finance • 26 days ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH, Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 20... Full story

Yahoo Finance • 29 days ago

Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus

Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and the Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) ending the week in the red as the AI trade came under... Full story

Yahoo Finance • last month

Viatris signs agreements with Biocon on $815m stake sale

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris will sell all of its convertible preferred equity in Biocon Biologics. The deal value comprises $415m in newly issu... Full story

Yahoo Finance • last month

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal

[Female scientist using microscope while working in laboratory] Thomas Barwick Viatris (VTRS [https://www.prnewswire.com/news-releases/viatris-announces-agreement-to-monetize-its-equity-stake-in-biocon-biologics-limited-302634606.html#fin... Full story

Yahoo Finance • last month

Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln

(RTTNews) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the agreements, Biocon will acquire all of Viatris' convertibl... Full story

Yahoo Finance • 2 months ago

Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fu... Full story

Yahoo Finance • 2 months ago

Cold Agglutinin Disease (CAD) Market Analysis, Business Prospects, Case Studies and Competitive Intelligence 2025-2035

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cold Agglutinin Disease Market - A Global and Regional Analysis: Focus on Drug Class, Dosage Form, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's... Full story

Yahoo Finance • 2 months ago

Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets

We recently published 10 Stocks on a Hot Streak. Viatris Inc. (NASDAQ:VTRS) is one of the best-performing stocks on Tuesday. Viatris rallied for a third day on Tuesday, jumping 10.13 percent to close at $11.20 apiece after reaffirming its... Full story

Yahoo Finance • 2 months ago

FDA to remove “black box” warnings on hormone therapies for menopause

[FDA Headquarters - White Oak Campus] hapabapa Marking a pivotal moment in women’s health, the U.S. Food and Drug Administration (FDA) on Monday initiated actions to remove “black box” warnings, the agency’s strongest safety alert, from h... Full story

Yahoo Finance • 2 months ago

Most S&P 500 healthcare stocks deliver earnings beat this week

21 out of 60 S&P 500 health care companies reported quarterly results this week, of which 20 delivered an earnings beat, and one came in-line with estimates. 16 of the reporting companies exceeded revenue consensus, while five trailed exp... Full story

Yahoo Finance • 2 months ago

Viatris plans Q1 2026 investor event to outline multiyear cost savings and innovation strategy

Earnings Call Insights: Viatris Inc. (VTRS) Q3 2025 MANAGEMENT VIEW * CEO Scott Smith opened by stating Viatris delivered "another strong quarter by focusing on our 2025 strategic priorities, driving strong commercial execution, advanc... Full story

Yahoo Finance • 2 months ago

Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players

Company Logo Key market opportunities for needle-free devices lie in technological advancements, regional expansion across Asia-Pacific and MEA, and growing applications in vaccines, pain management, and insulin delivery. Strategic allian... Full story

Yahoo Finance • 2 months ago

Viatris raises outlook as emerging markets drive Q3 beat

[Quarterly results] CharlieAJA/iStock via Getty Images Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) shares recorded modest gains in the premarket on Thursday after the Xanax maker exceeded Street forecasts with its Q3 2025 financ... Full story

Yahoo Finance • 3 months ago

Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc

​Viatris Inc. (NASDAQ:VTRS) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 15, Viatris Inc. (NASDAQ:VTRS) announced completing the acquisition of Aculys Pharma, Inc., which is a clinical-stage biopharmaceutical com... Full story

Yahoo Finance • 3 months ago

FDA introduces program to expedite review of domestic generic drugs

[The search for right medication] gerenme/iStock via Getty Images The U.S. Food and Drug Administration has introduced a new pilot program aimed at accelerating the review process for generic drugs that are both tested and produced entire... Full story

Yahoo Finance • 4 months ago

Viatris rises after a steep seven-day slide

Viatris (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]) rose 2.93% on Wednesday to $9.84, breaking a sharp seven-session decline. Over the past seven trading days, VTRS shed around 9%, with daily losses including a 3.61% drop on Sept... Full story

Yahoo Finance • 4 months ago

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed from the 2020 merger of Mylan and Pfizer’s Upjohn division... Full story